Best percentage reduction in target lesion burden over baseline in all response-evaluable patients. Dotted line indicates 50% reduction, consistent with a response (per investigator assessment, according to revised 2007 International Working Group [IWG] criteria). Blue, DLBCL de novo; red, transformed lymphoma.